Addex ceo steps down

Replacement being sought for Swiss allosteric modulators developer

Vincent Mutel has stepped down from his position as chief executive of Addex Pharmaceuticals, a Swiss developer of allosteric modulators for human health based in Geneva.

André Mueller, chairman of Addex, will act as executive chairman and lead an operational subcommittee of directors to manage the transition until a new ceo is appointed.

Under Mutel's leadership, Addex says it has become a world leader in the field of allosteric modulator drug discovery and has formed significant drug development partnerships with leading pharmaceutical companies.

The board of directors has invited Mutel to consider a possible future advisory role at Addex.

You may also like

Research & Development

Addex moves R&D operations to Campus Biotech in Geneva

To advance its portfolio of allosteric modulator drug candidates
Research & Development

Addex cuts staff from 19 to 2 people

CEO Bharatt Chowira and executive management step down
Research & Development

Addex to cut 28 jobs at Geneva operation

This is a strategic move from a position of strength, says ceo
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Masters of synthesis

Medicinal chemists take an initial lead compound and through systematic design work improve its potency, efficacy, and properties such as solubility and metabolism. The aim is to create a molecule that is effective, has few side-effects and can be scaled up, initially for clinical trials and subsequently for commercial manufacturing.
Research & Development

Addex makes job cuts to reduce costs

Restructures to focus on core r&d programmes and strategic partnerships
Research & Development

Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Research & Development

Lilly’s Jaypirca outperforms Imbruvica in landmark Phase III CLL trial, showing higher response rates and strong PFS trend

Pirtobrutinib met its primary endpoint and delivered higher overall response rates than ibrutinib in the BRUIN CLL-314 study, with early progression-free survival data also favouring Lilly’s next-generation BTK inhibitor
Subscribe now